Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

BACKGROUND: Immunotherapy is being tested in early‐stage non‐small cell lung cancer (NSCLC), and achieving higher rates of complete pathological responses (CPR) as compared to standard of care. Early identification of CPR patients has vital clinical implications. In this study, we focused on basal p...

Descripción completa

Detalles Bibliográficos
Autores principales: Laza‐Briviesca, Raquel, Cruz‐Bermúdez, Alberto, Nadal, Ernest, Insa, Amelia, García‐Campelo, María del Rosario, Huidobro, Gerardo, Dómine, Manuel, Majem, Margarita, Rodríguez‐Abreu, Delvys, Martínez‐Martí, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé Caro, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Viteri, Santiago, Massuti, Bartomeu, Casarrubios, Marta, Sierra‐Rodero, Belén, Tarín, Carlos, García‐Grande, Aránzazu, Haymaker, Cara, Wistuba, Ignacio I., Romero, Atocha, Franco, Fernando, Provencio, Mariano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288017/
https://www.ncbi.nlm.nih.gov/pubmed/34323406
http://dx.doi.org/10.1002/ctm2.491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288017/
https://www.ncbi.nlm.nih.gov/pubmed/34323406
http://dx.doi.org/10.1002/ctm2.491

Ejemplares similares